Actively Recruiting
Safety and Efficacy Study of MK-2010 Combined With Sacituzumab Tirumotecan for Advanced Solid Tumors
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-15
200
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating new treatments for certain advanced solid tumors, which are cancers found mostly in organs and tissues rather than in blood or fluids. These tumors may have spread or returned after previous treatments and may not be treatable with surgery or radiation. The study focuses on evaluating MK-2010 combined with sacituzumab tirumotecan sac-TMT, an antibody-drug conjugate designed to target and destroy cancer cells. The trial aims to assess the safety and tolerability of this combination and observe how many participants experience tumor shrinkage or disappearance. Participants receive MK-2010 and sac-TMT through intravenous infusions. The trial includes two parts a safety lead-in cohort and signal-finding cohorts using the dose determined in the first part. Premedications such as histamine receptor antagonists, acetaminophen, and dexamethasone are given according to approved guidelines to manage potential side effects. Emergency medications like epinephrine are also available as needed. Throughout the study, participants undergo regular evaluations to monitor safety, side effects, and treatment responses, including adverse events and dose-limiting toxicities. Outcome measures include the objective response rate and duration of response over several years. Drug levels and immune responses are also assessed periodically. The trial spans several years, with ongoing monitoring to understand the treatments impact and tolerability.
CONDITIONS
Brief Title
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here